Literature DB >> 24008819

Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers.

Guihua Huang1, Huazhang Liu1, Qing Tang2, Pengcheng Yu2, Xinxin Shen2, Yibin Zhang1, Xiangyi Liu1, Qing Cao1, Chuanxi Fu1, Beiyan Liu1, Ming Wang1.   

Abstract

BACKGROUND: Rabies is fatal in nearly 100% of cases, making post-exposure prophylaxis (PEP) a required measure for preventing mortality. Currently, the rabies vaccination regimen requires at least three to five clinic visits, with vaccination and transportation costs being very high. This study assessed the safety and efficacy of the 2-1 intramuscular (IM) regimen for rabies immunization with the goal of making rabies prophylaxis more economical.
METHODS: One-hundred and eighty-one subjects were divided into two groups: 79 subjects in test group A and 102 subjects in control group B. 2-1 IM regimen was chosen for group A and the Essen regimen was adopted for group B. Serum samples were also collected at D0, D7, D14, D45, D180, and D360 to determine the rabies serum neutralizing antibody by rapid luorescent focus inhibition test (RFFIT).
RESULTS: There was no significant difference between groups A and B with respect to the rate of adverse events following each vaccination. Nine-hundred and nineteen blood samples were obtained. At D0 (prior to immunization), all study subjects exhibited a geometric mean titer (GMT)<0.05 IU/ml. On D14, all study subjects exhibited NAb titers>0.5 IU/ml; titers above 0.5 IU/ml were maintained in both groups through D45 and D180 before gradually declining. The percentage of subjects positive for NAbs in group A and group B on D7 were 88.6% and 87.3%, respectively, which was not statistically different (P=0.545). On D360, the percentage of subjects positive for NAbs in group A and group B were 93.9% and 100% (P<0.01), respectively. During the study, the GMT was highest for both groups on D14 (21.90 IU/ml, group A; 19.93 IU/ml, group B) (P=0.045). On D45, the GMTs were 8.28 IU/ml (group A) and 7.89 IU/ml (group B) (P=0.037). On D7, D180, and D360, there were no statistically significant differences between the two groups with respect to the GMT.
CONCLUSIONS: The 2-1 IM regimen demonstrates the same safety and efficacy as the Essen regimen. The use of the 2-1 IM regimen could not only reduce the personal economic burdens of rabies immunization but also improve rabies immunization rates through fewer office visits and compliance with immunization procedures. However, further evaluation is needed before a major recommendation can be made.

Entities:  

Keywords:  geometric mean titer; immunization regimen; rabies; rabies vaccine; safety

Mesh:

Substances:

Year:  2013        PMID: 24008819      PMCID: PMC4181004          DOI: 10.4161/hv.26264

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  22 in total

1.  The serial cultivation of human diploid cell strains.

Authors:  L HAYFLICK; P S MOORHEAD
Journal:  Exp Cell Res       Date:  1961-12       Impact factor: 3.905

2.  One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine.

Authors:  S Chutivongse; H Wilde; D B Fishbein; G M Baer; T Hemachudha
Journal:  Vaccine       Date:  1991-08       Impact factor: 3.641

3.  Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group.

Authors:  J Lang; G H Simanjuntak; S Soerjosembodo; C Koesharyono
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

4.  Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine.

Authors:  R Vodopija; M Lafont; Z Baklaić; M Ljubicić; M Svjetlicić; I Vodopija
Journal:  Vaccine       Date:  1997-04       Impact factor: 3.641

5.  Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children.

Authors:  Chuanxi Fu; Qing He; Jianxiong Xu; Huaping Xie; Peng Ding; Wensui Hu; Zhiqiang Dong; Xiangyi Liu; Ming Wang
Journal:  Vaccine       Date:  2012-11-02       Impact factor: 3.641

6.  An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis.

Authors:  M J Warrell; D A Warrell; P Suntharasamai; C Viravan; A Sinhaseni; D Udomsakdi; R Phanfung; C Xueref; J C Vincent-Falquet; K G Nicholson; D Bunnag; T Harinasuta
Journal:  Lancet       Date:  1983-08-06       Impact factor: 79.321

Review 7.  Current issues in human rabies immunization.

Authors:  I Vodopija
Journal:  Rev Infect Dis       Date:  1988 Nov-Dec

8.  [Post-exposure antirabies vaccination. Early serological response to vaccine cultivated on VERO cells using a reduced 2-1-1 schedule].

Authors:  F Colnot; P Sureau; J L Alexandre; J P Arnaudo; J Y Hesse; H Jeanmaire
Journal:  Presse Med       Date:  1994-11-12       Impact factor: 1.228

9.  An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule.

Authors:  I Vodopija; P Sureau; M Lafon; Z Baklaic; M Ljubicić; M Svjetlicić; S Smerdel
Journal:  Vaccine       Date:  1986-12       Impact factor: 3.641

10.  WHO Expert Consultation on rabies.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2005
View more
  5 in total

1.  Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above.

Authors:  Jing Wang; FengJi Luo; ZiJian Feng; Li Li; YunHua Bai; Xing Ai; JianXin Ma; Zheng Zhang; NianMin Shi
Journal:  Hum Vaccin Immunother       Date:  2017-01-02       Impact factor: 3.452

2.  Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen).

Authors:  B J Mahendra; Dh Ashwath Narayana; Sharad Agarkhedkar; H S Ravish; B R Harish; Shalaka Agarkhedkar; S N Madhusudana; Ashwin Belludi; Khaleel Ahmed; Rekha Jonnalagedda; Hoshang Vakil; Chiranjiwi Bhusal; Ashwani Kumar Arora
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.

Authors:  Nianmin Shi; Yibin Zhang; Huizhen Zheng; Zhenggang Zhu; Dingming Wang; Sihai Li; Yuhua Li; Liqing Yang; Junnan Zhang; Yunhua Bai; Qiang Lu; Zheng Zhang; Fengji Luo; Chun Yu; Li Li
Journal:  Hum Vaccin Immunother       Date:  2017-01-25       Impact factor: 3.452

Review 4.  Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.

Authors:  Tim K Mackey; Bryan A Liang; Raphael Cuomo; Ryan Hafen; Kimberly C Brouwer; Daniel E Lee
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

5.  Human rabies in Côte d'Ivoire 2014-2016: Results following reinforcements to rabies surveillance.

Authors:  Issaka Tiembré; Anaïs Broban; Joseph Bénié; Mathilde Tetchi; Sophie Druelles; Maïna L'Azou
Journal:  PLoS Negl Trop Dis       Date:  2018-09-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.